



نتقدم بثقة  
Moving Forward  
With Confidence

رؤية عُمان  
2040  
Oman Vision

To:

**THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES**  
**Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)**  
**Director General of Engineering Affairs, MOH**  
**Director General of Royal Hospital**  
**Director General of Khoula Hospital**  
**Director General of Medical Supplies (MOH)**  
**Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)**  
**Hospital Director (Al Nahda Hospital)**  
**Hospital Director (Al Massara Hospital)**  
**The Head of Medical Services in SQU Hospital**  
**The Head of Medical Services in Royal Oman Police**  
**The Head of Medical Services in Ministry of Defence**  
**The Head of Medical Services in The Diwan**  
**The Head of Medical Services in The Sultan's Special Force**  
**The Head of Medical Services in Internal Security Services**  
**The Head of Medical Services in Petroleum Development of Oman**  
**The Head of Medical Services in LNG Oman**  
**ALL PRIVATE PHARMACIES & DRUG STORES**

After Compliments,

Please find attached our Circular No 125 dated 21/6/2023 Regarding NCMDR Recall of QIAstat-Dx® Gastrointestinal Panel from (mfr: QIAGEN Ltd).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information



**PADDC**  
المديرية العامة للصيدلة والرقابة الدوائية  
Directorate General of Pharmaceutical  
Affairs & Drug Control



ص.ب: ٣٩٣ مسقط - الرمز البريدي: 100 - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩

P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489

dgpa\_dc Email: dg-padc@moh.gov.om



Circular No. 125 / 2023

نتقدم بثقة  
Moving Forward  
with Confidence



03 -12-1444 H

21 -06-2023

**Recall of QIAstat-Dx® Gastrointestinal Panel from QIAGEN Ltd.**

Source	NCMDR - National Center Medical Device Reporting- SFDA. <a href="https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&amp;rid=19554">https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&amp;rid=19554</a>
Product	QIAstat-Dx® Gastrointestinal Panel.
Description	IVD.
Manufacturer	QIAGEN Ltd
Local agent	Taiba Medserv.
The affected products	REF 691411 LOTS 220218 and 220224
Reason	Cartridges of above lots do have a defect that would not allow detection of Shigalike toxin producing E. coli (STEC) that carries a less common subtype of the stx2 gene (stx2f). Samples containing STEC carrying the stx2f variant would be called as negative for STEC.
Action	1. If you have remaining stock of above listed LOTS, please do not use it, dispose it and contact your local dealer for replacement. Please re-evaluate severe cases reported as EPEC when tested with listed lots for potential STEC subtype stx2f cases for epidemiology reporting purposes. 2. Contact the local agent for remedial action.
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: <a href="mailto:Med-device@moh.gov.om">Med-device@moh.gov.om</a>

Dr. Mohammed Hamdan Al Rubaie

Director General

